Rodman & Renshaw Initiates Coverage on Enanta Pharmaceuticals (NASDAQ:ENTA)

Analysts at Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a note issued to investors on Thursday. The firm set a “buy” rating and a $20.00 price target on the biotechnology company’s stock. Rodman & Renshaw’s price target indicates a potential upside of 64.34% from the company’s previous close.

Several other research firms have also recently commented on ENTA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.29.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $12.17 on Thursday. Enanta Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $17.15. The firm has a 50 day simple moving average of $13.45 and a 200-day simple moving average of $12.59. The stock has a market cap of $353.17 million, a price-to-earnings ratio of -3.80 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%.The business had revenue of $18.62 million for the quarter, compared to the consensus estimate of $16.14 million. On average, equities analysts expect that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth about $32,000. Seven Fleet Capital Management LP acquired a new position in Enanta Pharmaceuticals during the fourth quarter valued at approximately $36,000. Strs Ohio acquired a new stake in shares of Enanta Pharmaceuticals in the fourth quarter worth $50,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enanta Pharmaceuticals by 333.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 2,758 shares during the period. Finally, Quarry LP acquired a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at $81,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.